Eloxx Pharmaceuticals, Inc. quarterly report, Q2 FY2016

Business context and reporting period

The supplied filing is Sevion Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2015, covering its fiscal second quarter and first six months of fiscal 2016 (fiscal year ending June 30). It is not identified as a filing by Eloxx Pharmaceuticals, Inc.; verify that this is the intended filing.

Sevion was a development-stage biotechnology company pursuing antibody therapeutics for cancer and immunological diseases. Its lead candidates included SVN001 and SVN002. Management said research spending on its antibody program had been reduced pending a strategic or financing transaction.

Key financial metrics

MetricThree months ended Dec. 31, 2015Six months ended Dec. 31, 2015Comparison
Licensing revenue$37,500$75,000$0 in the comparable 2014 periods
Operating loss$3.76 million$4.91 million2014: $10.75 million and $15.93 million
Net loss$3.86 million$4.04 million2014: $10.75 million and $15.93 million
Loss per common share$0.19$0.212014: $0.78 and $1.15
Research and development expense$595,000$1.20 millionDown 56.6% and 65.8%, respectively, year over year
General and administrative expense$401,000$988,000Down 68.0% and 51.3%, respectively, year over year

For the six months, operating cash use was $2.12 million, investing cash flow was zero, and financing provided $1.15 million. Cash declined $968,053 to $2.37 million. At December 31, current assets were $2.69 million, current liabilities $569,155, and working capital $2.12 million. Total liabilities were $6.92 million, including $2.33 million of warrant and stock-right liabilities and a $3.92 million deferred tax liability; the filing does not show conventional borrowings. No gross margin is presented.

Changes, outlook, and risks

  • Losses decreased substantially year over year, primarily because of reduced R&D, closure of the New Jersey office, and staff reductions—not because of material revenue growth. Revenue was limited to amortization of deferred collaboration revenue.
  • The company recorded a $2.8 million goodwill impairment in the quarter after a decline in market value. Goodwill was $2.98 million at period-end; acquired research and development of $9.8 million was not impaired. The 2014 comparison included an $8.12 million goodwill impairment and $2.29 million patent write-off.
  • Management estimated cash would fund operations through at least June 30, 2016, but said additional capital was needed. Planned funding sources included equity or debt, strategic transactions, and licensing; there was no assurance financing would be available on acceptable terms. Failure to raise funds could force program cuts, licensing, a sale, cessation of operations, or bankruptcy.
  • A Janssen-affiliate collaboration provided upfront and research-support payments; Sevion could potentially receive development and commercial milestones totaling up to $125 million plus low-single-digit royalties if candidates are licensed and milestones achieved. These amounts are contingent, not current revenue or assured proceeds.
  • Disclosure controls and internal control over financial reporting were deemed ineffective due to an unremediated material weakness in review and calculation of equity-linked instruments; management reported a material financial-statement adjustment. This is a significant reporting risk.
  • Other material risks include recurring losses and going-concern uncertainty, dependence on external financing and research partners, clinical and regulatory uncertainty, intellectual-property risks, and potential shareholder dilution. Outstanding warrants, options, and convertible preferred stock could materially increase shares outstanding.

Important facts to verify

  • Confirm the intended issuer: this document names Sevion Therapeutics, not Eloxx Pharmaceuticals.
  • Verify the reported cash runway and financing needs against subsequent filings and financing events.
  • Check progress in remediating the equity-linked-instrument control weakness and any later corrections or restatements.
  • Review the terms, status, and contingent economics of the Janssen collaboration and any subsequent licensing milestones.
  • Assess potential dilution from warrants, options, and preferred-stock conversion, including any exercise-price or anti-dilution provisions.